Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Shoujie Huang(Xiamen University), Ningshao Xia(Xiamen University), Huirong Pan, Xingcheng Huang(Xiamen University), Chunlan Zhuang(Xiamen University), Xiaowen Hu(Xiamen University), Zhongze Wang, Wentong Shen, Changlin Yang, Xuefeng Zhang(Mississippi State University), Xia Zang, Kongxin Zhu(Xiamen University), Ying Dong(Xiamen University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Zimin Tang(Xiamen University), Zizheng Zheng(Xiamen University), Xiaohui Liu(Xiamen University), Jun Zhang(University of Southern California), Yijun Wang, Ting Wu(Xiamen University), Yingying Su(Nanjing Medical University), Donglin Liu, Qi Chen(Xiamen University), Quan Tang, Han-Min Jiang, Yue Huang(Fujian Medical University), Huanhuan Cao, Shengxiang Ge(Xiamen University)
Cited by 70
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204
Recent Progress on the Versatility of Virus-Like Particles
|Vaccines|2020|171
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|bioRxiv (Cold Spring Harbor Laboratory)|2020|168
Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma
|Journal of Cancer|2018|124